A Phase 4 interventional study of Testosterone Gel (Androgel) and Placebo in Hypogonadism and Atherosclerosis, sponsored by Brigham and Women's Hospital. Completed at 3 sites in United States. Open to male participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-29.
Sponsored by Brigham and Women's Hospital · Phase 4, Interventional, and Treatment
As men grow older, their testosterone levels decrease with age. One-third of men, 70 years of age or older, have low testosterone levels. It is known that short-term testosterone replacement is safe, and can increase muscle strength and physical function, but the risks of long-term testosterone replacement in older men with low testosterone levels are incompletely understood.
Atherosclerosis is characterized by thickening of the artery walls, and the narrowing of the blood vessels as cholesterol is deposited in the lining of the arteries. It is the major cause of cardiovascular disease including ischemic heart disease (heart attacks) and stroke. Although, historically, there has been a widespread perception that higher levels of testosterone might increase the risk of atherosclerosis, the evidence from research does not support this. In observational studies, higher testosterone levels have been correlated with more favorable cardiovascular risk factors, and supplementation with testosterone to bring older men into the normal range for healthy younger men appears to improve several cardiovascular risk factors, and may slow the progression of atherosclerosis.
The primary purpose of this study is to look at the effects of testosterone replacement on the progression of atherosclerosis in older men. This study is also being done to find out whether replacement with testosterone in older men with low testosterone levels improves their health-related quality of life.
Although short-term administration of testosterone in replacement doses is relatively safe, the risks of long-term testosterone administration in older men remain poorly understood. The two major areas of concern include the potential for increased risk of atherosclerotic heart disease and exacerbation of a pre-existing, subclinical prostate cancer. There is a widespread perception that testosterone supplementation adversely affects plasma lipoprotein profile and increases the risk of atherosclerotic heart disease; this premise is not supported by data. Thus, the long-term consequences of testosterone supplementation on the risk of atherosclerosis progression remain unknown. While supraphysiological doses of testosterone and non-aromatizable androgens frequently employed by body-builders undoubtedly decrease plasma high density lipoprotein (HDL)-cholesterol levels, physiologic testosterone replacement in older men has been associated with only a modest or no decrease in plasma HDL-cholesterol. Cross-sectional studies of middle-aged men find a direct, rather than an inverse, relationship between serum testosterone levels and plasma HDL-cholesterol concentrations as well as an inverse correlation between serum testosterone levels and visceral fat volume. Testosterone supplementation of middle-aged men with truncal obesity is associated with a reduction in visceral fat volume, serum glucose concentration, blood pressure, and an improvement in insulin sensitivity. All of these changes are associated with lower risk for atherosclerosis. These data suggest that serum testosterone levels in the range that is mid-normal for healthy young men are consistent with an optimal cardiovascular risk profile at any age, and that testosterone concentrations either above or below the physiologic male range may increase the risk of atherosclerotic heart disease. Studies in a low density lipoprotein (LDL)-receptor deficient mice provide compelling evidence that testosterone retards early atherogenesis, and that testosterone effects on atherogenesis are mediated through its conversion to estradiol by the action of aromatase enzyme that is expressed in the vessel wall. The effects of testosterone replacement on cardiovascular risk in humans have never been directly examined. Therefore, the primary objective of this study is to examine directly the effects of testosterone replacement on atherosclerosis progression in men by measuring common carotid artery intima-media thickness (CCA IMT) and coronary artery calcification (CAC) by multidetector computed tomography (MDCT), two independent measurements of generalized atherosclerosis.
The second objective of this study is to determine whether physiologic testosterone replacement of older men with low testosterone levels improves health-related quality of life. Aging-associated decline in physical, sexual, and cognitive functions contributes to diminished quality of life in older men. Although the pathophysiology of impairment in each of these subdomains of health-related quality of life is complex and multifactorial, one correctable cause of the diminished quality of life in older men is the decrease in serum testosterone concentrations. Total and free testosterone (T) levels decline with advancing age in normal men, with a significant number of men meeting usual criteria for hypogonadism by the sixth to seventh decades. Spontaneous and experimentally-induced androgen-deficiency in young men is associated with decreased muscle mass and strength and impaired sexual function. Because loss of muscle mass and function contributes to diminished health-related quality of life (HRQOL) in older men, anabolic therapies such as testosterone that increase muscle mass and strength, would be expected to improve physical function. In older men with low testosterone levels, testosterone might also improve sexual function and marital interaction. A growing body of literature suggests that testosterone impacts neuronal functioning and may affect cognitive performance. Because physical, sexual, and cognitive functions are important determinants of health-related quality of life, testosterone replacement of older men with low testosterone levels would be expected to improve general health perceptions.
The aging of humans is a recent evolutionary event. Of the thousand generations of men and women who have lived on this planet, only the humans of the last two generations could have hoped to live past the age of 50. The population is getting proportionally older. The number of people 85 years of age and older today is substantially greater than at the beginning of the 20th century. Advancing age is associated with decreased muscle mass and strength, and impairment of physical, sexual, and cognitive functions. Diminished muscle mass and strength increases the risk of falls, disability and poor quality of life. Age-related impairment of sexual and cognitive functions also contributes to overall reduction in quality of life. Testosterone replacement, by improving some aspects of physical, sexual and cognitive functions, would be expected to improve health-related quality of life.
Previous studies have established that testosterone replacement in older men with low testosterone levels increases muscle mass and strength. However, lack of information in two areas has prevented formulation of general recommendations about wider use of testosterone replacement in older men. First, the effectiveness of testosterone in improving physical function, quality of life, and other health-related outcomes has not been demonstrated. Second, while there is agreement that short-term administration of testosterone in replacement doses is safe, the long-term risks of testosterone supplementation in older men remain unknown. The areas of major concern are the risks of prostate cancer and heart disease. Because of the high prevalence, even small increases in the incidence rates of atherosclerotic heart disease associated with testosterone supplementation will have significant impact on overall morbidity and mortality, and health care costs. The study will evaluate one important aspect of the long-term safety of testosterone administration by directly examining its effects on the rate of progression of atherosclerosis. If the study demonstrates that testosterone retards atherosclerosis progression, then that would provide one additional reason for testosterone supplementation of older men with low testosterone levels. If the study demonstrates a neutral effect of testosterone on atherosclerosis progression, that information would also be reassuring and useful to regulatory agencies. This study will establish the efficacy of testosterone replacement in improving physical, sexual and cognitive functions that are major determinants of health-related quality of life in older men.
In spite of the paucity of efficacy and safety data, the sales of testosterone and other androgenic products have witnessed explosive growth because of increased media attention and public interest. During the summer of 2000, testosterone-related stories were on the cover of Time, Newsweek, New York Times, and Los Angeles Times. The prescription sales of testosterone that had been growing at 25-30% annual rate since 1993, almost doubled in the year 2000, and have cumulatively increased 500% since 1993 (Source: IMS Sales Data, provided by Reed Selby, Marketing Director for ALZA Corporation). The growing testosterone use in older men, without a clear understanding of its benefits or long-term risks, has raised concern among regulatory agencies. The proposed study by providing definitive information on the effects of testosterone replacement on several measures of efficacy and safety in older men would facilitate an analysis of its risk:benefit ratio.
1,567 studies on the registry are indexed under Atherosclerosis; 264 are open to participants now.
This study's enrollment of 308 is above the median of 106 across 882 interventional studies indexed under Atherosclerosis.
Browse Atherosclerosis studies →Brigham and Women's Hospital is the lead sponsor of 1,236 studies on the registry; 224 are open to participants now.
Of its 116 completed or terminated interventional studies of FDA-regulated products, 64 (55%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
epilepsy, multiple sclerosis, human immunodeficiency virus (HIV), Parkinson's disease, stroke
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
Drug: Testosterone Gel (Androgel)
Participants received placebo-matching testosterone gel daily for 3 years.
Drug: Placebo
7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years
Placebo-matching testosterone gel daily for 3 years
Change From Baseline in Common Carotid Artery Intima-Media Thickness (IMT)
B-mode carotid artery images for IMT were acquired from the far wall of the distal centimeter of the right carotid artery with high-resolution ultrasound equipment. IMT is used as a predictor of the incidence of cardiovascular events. An increase in the IMT thickness is associated with a higher incidence of cardiovascular events. Less thickening is best. Change is expressed in millimeters (mm).
Time frame: Baseline and Month 36
Change From Baseline in Coronary Artery Calcium Score
A multiple detector computed tomography (MDCT) scan was performed. Proximal coronary arteries were visualized, and at least 30 consecutive images were obtained at 3-mm intervals. Coronary calcium was defined as a plaque of at least 3 contiguous pixels (area, 1.02 mm\^2) with a density of more than 130 Hounsfield units.The lesion score was calculated by multiplying lesion area by a density factor derived from Hounsfield units. The Agatston method was used to determine the total calcium score by summing the lesion scores from the left main, left anterior descending, circumflex, and right coronary arteries. The Agatston score is the measure of calcification in arteries expressed on continuous scale with "0" value (better) indicating no calcification and score above 400 (worse) indicating high calcification. There is no upper limit for this measure. A positive change from baseline indicates a worsening.
Time frame: Baseline and Month 36
Change From Baseline in Lipid Profiles
Laboratory tests included in the lipid profile were Total Cholesterol, High Density Lipoprotein-Cholesterol (HDL-C), Low Density Lipoprotein-Cholesterol (LDL-C) and Triglycerides.Lower values for Total Cholesterol, LDL-C are better and a negative change from Baseline indicates improvement. Higher values for HDL-C are better and a positive change from Baseline indicates improvement.
Time frame: Baseline and Month 36
Changes in Biomarkers of Inflammation
Time frame: Three years
Changes in Blood Pressure
Time frame: Three years
Change From Baseline in Complex Figure (Immediate) and Complex Figure (Delayed)
Cognitive Function was assessed by Complex Figure (Immediate) and (Delayed). The Complex Figure Test consists of three tasks: copy, immediate recall, and delayed recall. Participants were presented with a complex design and then asked to draw the same figure. Subsequently, they were instructed to draw what they remembered immediately, and after a 30 minute delay. Scoring was based on the number of correct items for a total possible score of 0 (worst) to 36 (Best). A positive change from Baseline indicates improvement. A negative change from Baseline indicates a worsening.
Time frame: Baseline and Month 36
Change From Baseline in Paragraph Recall Test (Delayed)
Cognitive Function was assessed by the Paragraph Recall Test (Delayed). In the Paragraph Recall Test, participants were read two short paragraphs and asked to recall them immediately and after a 30 minute delay, using the exact words that were read aloud. Scoring was based on the number of items correctly recalled. More items correctly recalled is best and a positive change from Baseline indicates improvement.
Time frame: Baseline and Month 36
Change From Baseline in the Buschke Selective Reminding Test (Delayed)
Cognitive function was assessed by the Buschke Selective Reminding Test. In the Buschke Selective Reminding Test, participants were read 12 words and asked to recall as many words as possible. Subsequent trials included only those words that were not recalled in the preceding trial. Individuals were also asked to recall the list 30 minutes later. To assess phonemic and category fluency, participants were asked to name as many items from a given category as possible in 1 minute. Higher number of correct items is best and a positive change from Baseline indicates improvement.
Time frame: Baseline and Month 36
Change From Baseline in the Verbal Fluency Test
Cognitive function was assessed by the Verbal Fluency Test. Participants were asked to name as many letters from a given category as possible in 1 minute. Higher number of letters is best and a positive change from Baseline indicates improvement.
Time frame: Baseline and Month 36
Change From Baseline in the Category Fluency Test
Cognitive function was assessed by the Category Fluency Test. Participants were asked to name as many items from a given category as possible. Higher number of items named is best and a positive change from Baseline indicates improvement.
Time frame: Baseline and Month 36
Change From Baseline in the Stroop Interference Test
Cognitive function was assessed by the Stroop Interference Test. In the Stroop Interference Test, participants were presented with a word list of colors printed in ink of a color different from how the printed word read. Participants were instructed to read aloud the color of the ink in which a word was printed, while not verbalizing the word itself. The time in seconds that the items were correctly identified was recorded. Less time is better and a negative change from Baseline indicates improvement.
Time frame: Baseline and Month 36
Change From Baseline in the Trail Making Test B
Cognitive function was assessed by the Trail Making Test B. Trail Making Test B involved participants connecting numbers (1-13) and letters (A-L) alternately (1-A, 2-B, etc) on a piece of paper as quickly as possible. Scores represent the time it takes the participant to complete the test. Less time is best and a negative change from Baseline indicates improvement. A positive change from Baseline indicates a worsening.
Time frame: Baseline and Month 36
Change From Baseline in Chest Press Strength and Leg Press Strength
Maximal voluntary strength of the lower and upper extremities was assessed using the one repetition maximum (1-RM) method for the seated leg press and chest press exercises. Participants were positioned with standardized seat position and foot placement that allowed 90° of knee flexion for the leg press exercise. Seat height and handle position was standardized for the chest press. Participants were familiarized with the exercises, practiced the technique and completed a 5-minute warm-up. The 1-RM procedure consisted of a warm up set with 5 to 8 repetitions at a resistance set to about 50% of the participant's estimated 1-RM and progressed with increasing loads interspersed with standardized rest periods until the participant was able to perform only one full-range-of-motion repetition.
Time frame: Baseline and Month 36
Change From Baseline in Unloaded Stair Climb Power and Loaded Stair Climb Power
Physical Function was evaluated using two tests of stair climb power using an indoor 12-step staircase. One test consisted of ascending the 12-steps as rapidly as possible without running (unloaded stair climb) while the second test required participants to carry a load equivalent to 20% of their baseline body weight evenly distributed in two canvas tote bags (loaded stair climb). Time to ascend the stairs was measured electronically with a digital clock and switch mats placed at the base of the steps and on the 12th step. Power in watts is calculated by the following: \[body weight (kilograms) \* distance (meters)/ (time/60)\] /6.12. A negative change from Baseline indicates improvement.
Time frame: Baseline and Month 36
Change in Sexual Function as Assessed by the International Index of Erectile Function (IIEF)
IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (6 questions), orgasmic function (2 questions), sexual desire (2 questions), intercourse satisfaction (3 questions), and overall sexual satisfaction (2 questions). Each question was answered on a 5-point scale from 1 to 5 (best) with a total possible score range of 0 to 75 with higher scores representing better function. A positive change from Baseline indicates improvement.
Time frame: Baseline and Month 36
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
The SF-36 measures 8 domains of the QoL: physical function, bodily pain, vitality, role limitations due to physical problems, general health perceptions, emotional well-being, social function, and role limitations due to emotional problems. Each domain is scored separately from 0 to 100 with higher scores representing better health-related QoL. The Overall Score is the average of the individual domain scores. A negative change from Baseline indicates improvement.
Time frame: Baseline and Month 36
| Milestone | Testosterone | Placebo |
|---|---|---|
| Started | 156 | 152 |
| Intent-to-treat: received study drug | 155 | 151 |
| Completed | 111 | 100 |
| Not completed | 45 | 52 |
| Withdrew: Withdrew consent | 19 | 30 |
| Withdrew: Lost to follow-up | 5 | 4 |
| Withdrew: Death | 2 | 3 |
| Withdrew: Elevated hematocrit | 3 | 0 |
| Withdrew: Rash | 3 | 0 |
| Withdrew: Elevated prostate specific antigen | 2 | 0 |
| Withdrew: Stroke | 2 | 0 |
| Withdrew: Myocardial infarction | 1 | 0 |
| Withdrew: Lower urinary tract symptoms | 1 | 0 |
| Withdrew: Cognitive impairment | 1 | 0 |
| Withdrew: Pancreatic cancer | 1 | 3 |
| Withdrew: Sleep apnea | 1 | 0 |
| Withdrew: Shoulder pain | 1 | 0 |
| Withdrew: Inappropriate behaviour with staff | 1 | 0 |
| Withdrew: Nonadherence | 1 | 1 |
| Withdrew: Enrolled in another study | 1 | 0 |
| Withdrew: Major depression | 0 | 2 |
| Withdrew: Lung cancer | 0 | 2 |
| Withdrew: Elevated ipss score | 0 | 1 |
| Withdrew: Retroperitoneal cancer | 0 | 1 |
| Withdrew: Mastodynia and gynecomastia | 0 | 1 |
| Withdrew: Mood swings and irritability | 0 | 1 |
| Withdrew: Bradycardia | 0 | 1 |
| Withdrew: Itchy swollen eyes | 0 | 1 |
| Withdrew: Recurrent melanoma | 0 | 1 |
B-mode carotid artery images for IMT were acquired from the far wall of the distal centimeter of the right carotid artery with high-resolution ultrasound equipment. IMT is used as a predictor of the incidence of cardiovascular events. An increase in the IMT thickness is associated with a higher incidence of cardiovascular events. Less thickening is best. Change is expressed in millimeters (mm).
| mm | Testosterone | Placebo |
|---|---|---|
| Baseline | 0.877 ± 0.210 | 0.879 ± 0.199 |
| Change at Month 36 | 0.036 ± 0.059 | 0.033 ± 0.077 |
A multiple detector computed tomography (MDCT) scan was performed. Proximal coronary arteries were visualized, and at least 30 consecutive images were obtained at 3-mm intervals. Coronary calcium was defined as a plaque of at least 3 contiguous pixels (area, 1.02 mm\^2) with a density of more than 130 Hounsfield units.The lesion score was calculated by multiplying lesion area by a density factor derived from Hounsfield units. The Agatston method was used to determine the total calcium score by summing the lesion scores from the left main, left anterior descending, circumflex, and right coronary arteries. The Agatston score is the measure of calcification in arteries expressed on continuous scale with "0" value (better) indicating no calcification and score above 400 (worse) indicating high calcification. There is no upper limit for this measure. A positive change from baseline indicates a worsening.
| score on a scale | Testosterone | Placebo |
|---|---|---|
| Baseline | 451.78 ± 715.41 | 508.31 ± 694.87 |
| Change at Month 36 | 103.61 ± 289.45 | 124.54 ± 208.42 |
Laboratory tests included in the lipid profile were Total Cholesterol, High Density Lipoprotein-Cholesterol (HDL-C), Low Density Lipoprotein-Cholesterol (LDL-C) and Triglycerides.Lower values for Total Cholesterol, LDL-C are better and a negative change from Baseline indicates improvement. Higher values for HDL-C are better and a positive change from Baseline indicates improvement.
| mg/dL | Testosterone | Placebo |
|---|---|---|
| Total Cholesterol, Baseline | 187.15 ± 42.09 | 183.44 ± 36.68 |
| Total Cholesterol, Change at Month 36 | -14.88 ± 35.92 | -12.56 ± 33.90 |
| HDL-C, Baseline | 47.11 ± 11.97 | 48.71 ± 14.21 |
| HDL-C, Change at Month 36 | 0.18 ± 9.69 | 2.00 ± 11.08 |
| LDL-C, Baseline | 115.64 ± 35.18 | 109.66 ± 31.86 |
| LDL-C, Change at Month 36 | -11.24 ± 26.80 | -13.92 ± 30.80 |
| Triglycerides, Baseline | 142.695 ± 87.93 | 138.95 ± 76.37 |
| Triglycerides, Change at Month 36 | -19.41 ± 73.69 | -12.62 ± 84.62 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Cognitive Function was assessed by Complex Figure (Immediate) and (Delayed). The Complex Figure Test consists of three tasks: copy, immediate recall, and delayed recall. Participants were presented with a complex design and then asked to draw the same figure. Subsequently, they were instructed to draw what they remembered immediately, and after a 30 minute delay. Scoring was based on the number of correct items for a total possible score of 0 (worst) to 36 (Best). A positive change from Baseline indicates improvement. A negative change from Baseline indicates a worsening.
| correct items | Testosterone | Placebo |
|---|---|---|
| Complex Figure:Immediate, Baseline | 20.95 ± 6.50 | 20.31 ± 6.20 |
| Complex Figure:Immediate, Change at Month 36 | -1.25 ± 4.90 | -0.24 ± 6.11 |
| Complex Figure:Delayed, Baseline | 20.28 ± 6.08 | 19.75 ± 6.11 |
| Complex Figure:Delayed, Change at Month 36 | -0.49 ± 5.20 | -0.24 ± 5.74 |
Cognitive Function was assessed by the Paragraph Recall Test (Delayed). In the Paragraph Recall Test, participants were read two short paragraphs and asked to recall them immediately and after a 30 minute delay, using the exact words that were read aloud. Scoring was based on the number of items correctly recalled. More items correctly recalled is best and a positive change from Baseline indicates improvement.
| correct items | Testosterone | Placebo |
|---|---|---|
| Paragraph: Delayed, Baseline | 13.69 ± 6.37 | 13.57 ± 6.12 |
| Paragraph:Delayed, Change at Month 36 | 2.15 ± 6.05 | 1.72 ± 4.82 |
Cognitive function was assessed by the Buschke Selective Reminding Test. In the Buschke Selective Reminding Test, participants were read 12 words and asked to recall as many words as possible. Subsequent trials included only those words that were not recalled in the preceding trial. Individuals were also asked to recall the list 30 minutes later. To assess phonemic and category fluency, participants were asked to name as many items from a given category as possible in 1 minute. Higher number of correct items is best and a positive change from Baseline indicates improvement.
| correct items | Testosterone | Placebo |
|---|---|---|
| Buschke Total Correct Delayed, Baseline | 8.00 ± 2.80 | 7.76 ± 2.69 |
| Buschke Total Correct Delayed, Change at Month 36 | 0.47 ± 2.46 | 0.85 ± 2.21 |
Cognitive function was assessed by the Verbal Fluency Test. Participants were asked to name as many letters from a given category as possible in 1 minute. Higher number of letters is best and a positive change from Baseline indicates improvement.
| letters | Testosterone | Placebo |
|---|---|---|
| Baseline | 26.96 ± 10.25 | 27.02 ± 8.97 |
| Change at Month 36 | 2.86 ± 8.84 | 1.77 ± 7.35 |
Cognitive function was assessed by the Category Fluency Test. Participants were asked to name as many items from a given category as possible. Higher number of items named is best and a positive change from Baseline indicates improvement.
| items | Testosterone | Placebo |
|---|---|---|
| Category Fluency, Baseline | 18.07 ± 5.61 | 18.01 ± 5.62 |
| Category Fluency, Change at Month 36 | 2.25 ± 6.81 | 0.37 ± 6.77 |
Cognitive function was assessed by the Stroop Interference Test. In the Stroop Interference Test, participants were presented with a word list of colors printed in ink of a color different from how the printed word read. Participants were instructed to read aloud the color of the ink in which a word was printed, while not verbalizing the word itself. The time in seconds that the items were correctly identified was recorded. Less time is better and a negative change from Baseline indicates improvement.
| seconds | Testosterone | Placebo |
|---|---|---|
| Stroop Interference, Baseline | 55.64 ± 15.60 | 56.84 ± 15.85 |
| Stroop Interference, Change at Month 36 | -1.07 ± 14.48 | 0.99 ± 16.10 |
Cognitive function was assessed by the Trail Making Test B. Trail Making Test B involved participants connecting numbers (1-13) and letters (A-L) alternately (1-A, 2-B, etc) on a piece of paper as quickly as possible. Scores represent the time it takes the participant to complete the test. Less time is best and a negative change from Baseline indicates improvement. A positive change from Baseline indicates a worsening.
| seconds | Testosterone | Placebo |
|---|---|---|
| Trails B, Baseline | 98.52 ± 42.40 | 97.57 ± 31.82 |
| Trails B, Change at Month 36 | 3.88 ± 34.15 | 11.26 ± 40.61 |
Maximal voluntary strength of the lower and upper extremities was assessed using the one repetition maximum (1-RM) method for the seated leg press and chest press exercises. Participants were positioned with standardized seat position and foot placement that allowed 90° of knee flexion for the leg press exercise. Seat height and handle position was standardized for the chest press. Participants were familiarized with the exercises, practiced the technique and completed a 5-minute warm-up. The 1-RM procedure consisted of a warm up set with 5 to 8 repetitions at a resistance set to about 50% of the participant's estimated 1-RM and progressed with increasing loads interspersed with standardized rest periods until the participant was able to perform only one full-range-of-motion repetition.
| newton | Testosterone | Placebo |
|---|---|---|
| Chest Press Strength, Baseline | 516.99 ± 133.37 | 513.83 ± 104.92 |
| Chest Press Strength, Change at Month 36 | -12.73 ± 54.20 | -26.20 ± 40.88 |
| Leg Press Strength, Baseline | 2270.37 ± 424.81 | 2233.74 ± 416.06 |
| Leg Press Strength, Change at Month 36 | -37.26 ± 230.42 | -65.33 ± 251.94 |
Physical Function was evaluated using two tests of stair climb power using an indoor 12-step staircase. One test consisted of ascending the 12-steps as rapidly as possible without running (unloaded stair climb) while the second test required participants to carry a load equivalent to 20% of their baseline body weight evenly distributed in two canvas tote bags (loaded stair climb). Time to ascend the stairs was measured electronically with a digital clock and switch mats placed at the base of the steps and on the 12th step. Power in watts is calculated by the following: \[body weight (kilograms) \* distance (meters)/ (time/60)\] /6.12. A negative change from Baseline indicates improvement.
| watts | Testosterone | Placebo |
|---|---|---|
| Unloaded Stair Climb Power, Baseline | 536.33 ± 134.40 | 535.78 ± 125.70 |
| Unloaded Stair Climb Power, Change at Month 36 | -8.17 ± 71.60 | -12.89 ± 64.28 |
| Loaded Stair Climb Power, Baseline | 581.24 ± 148.73 | 594.84 ± 150.28 |
| Loaded Stair Climb Power, Change at Month 36 | -8.44 ± 70.56 | -12.76 ± 63.13 |
IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (6 questions), orgasmic function (2 questions), sexual desire (2 questions), intercourse satisfaction (3 questions), and overall sexual satisfaction (2 questions). Each question was answered on a 5-point scale from 1 to 5 (best) with a total possible score range of 0 to 75 with higher scores representing better function. A positive change from Baseline indicates improvement.
| score on a scale | Testosterone | Placebo |
|---|---|---|
| Erectile Function, Baseline | 18.33 ± 10.11 | 18.67 ± 10.64 |
| Erectile Function, Change at Month 36 | -0.15 ± 7.40 | -0.80 ± 7.55 |
| Orgasmic Function, Baseline | 7.37 ± 3.61 | 6.38 ± 3.86 |
| Orgasmic Function, Change at Month 36 | -0.65 ± 3.35 | 0.24 ± 3.44 |
| Sexual Desire, Baseline | 6.89 ± 2.04 | 6.58 ± 2.19 |
| Sexual Desire, Change at Month 36 | 0.18 ± 1.94 | 0.07 ± 1.87 |
| Intercourse Satisfaction, Baseline | 8.32 ± 5.92 | 8.14 ± 5.94 |
| Intercourse Satisfaction, Change at Month 36 | 0.05 ± 4.56 | -0.71 ± 4.11 |
| Overall Satisfaction, Baseline | 6.24 ± 2.84 | 6.12 ± 2.64 |
| Overall Satisfaction, Change at Month 36 | 0.40 ± 2.77 | 0.81 ± 2.54 |
| Total Score, Baseline | 48.48 ± 21.09 | 49.67 ± 23.25 |
| Total Score, Change at Month 36 | 0.22 ± 15.54 | -0.39 ± 15.32 |
The SF-36 measures 8 domains of the QoL: physical function, bodily pain, vitality, role limitations due to physical problems, general health perceptions, emotional well-being, social function, and role limitations due to emotional problems. Each domain is scored separately from 0 to 100 with higher scores representing better health-related QoL. The Overall Score is the average of the individual domain scores. A negative change from Baseline indicates improvement.
| score on a scale | Testosterone | Placebo |
|---|---|---|
| Energy/Fatigue, Baseline | 69.92 ± 18.47 | 71.21 ± 14.67 |
| Energy/Fatigue, Change at Month 36 | -1.45 ± 13.40 | -0.46 ± 12.57 |
| Emotional Well-Being, Baseline | 82.67 ± 12.64 | 83.17 ± 11.38 |
| Emotional Well-Being, Change at Month 36 | -1.16 ± 14.76 | 0.91 ± 11.60 |
| Role Limitations/Emotional Problems, Baseline | 90.00 ± 23.21 | 89.08 ± 26.04 |
| Role Limitations/Emotional Problems,Change | 3.51 ± 32.69 | -9.09 ± 34.00 |
| Social Functioning, Baseline | 90.42 ± 16.17 | 92.89 ± 13.06 |
| Social Functioning, Change at Month 36 | -3.29 ± 22.64 | -4.83 ± 14.06 |
| Physical Functioning, Baseline | 82.00 ± 20.15 | 83.28 ± 18.79 |
| Physical Functioning, Change at Month 36 | -3.82 ± 21.20 | -2.39 ± 21.09 |
| Role Limitations/Physical Health, Baseline | 80.00 ± 30.81 | 88.79 ± 21.55 |
| Role Limitations,/Physical Health, Change | -1.97 ± 24.23 | -9.66 ± 34.61 |
| Pain, Baseline | 82.83 ± 17.29 | 82.24 ± 15.84 |
| Pain, Change at Month 36 | -7.96 ± 14.81 | -5.97 ± 17.90 |
| General Health, Baseline | 74.17 ± 19.51 | 76.72 ± 15.18 |
| General Health, Change at Month 36 | -0.53 ± 11.90 | -3.75 ± 14.59 |
| Overall Score, Baseline | 81.50 ± 14.12 | 83.42 ± 12.45 |
| Overall Score, Change at Month 36 | -2.08 ± 11.88 | -4.40 ± 12.24 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Testosterone | — | 24/155 (15.5%) | 33/155 (21.3%) |
| Placebo | — | 25/151 (16.6%) | 20/151 (13.2%) |
| Event | Testosterone | Placebo |
|---|---|---|
| DeathGeneral disorders | 1/155 | 6/151 |
| Angina pectorisCardiac disorders | 1/155 | 3/151 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/155 | 2/151 |
| Cerebrovascular accident (CVA)Nervous system disorders | 3/155 | 0/151 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/155 | 0/151 |
| AngioplastySurgical and medical procedures | 2/155 | 0/151 |
| Myocardial infarctionCardiac disorders | 2/155 | 0/151 |
| Pulmonary carcinoma complicationsNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/155 | 1/151 |
| Pancreatic cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/155 | 1/151 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/155 | 1/151 |
| Event | Testosterone | Placebo |
|---|---|---|
| Elevated Prostate-Specific Antigen (PSA)Investigations | 16/155 | 9/151 |
| Upper respiratory infectionInfections and infestations | 12/155 | 12/151 |
| Elevated hematocrit (HCT)Investigations | 8/155 | 0/151 |
Intent-to-treat Population included all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Testosterone | Placebo | Total |
|---|---|---|---|
| Mean | 66.9 ± 5.0 | 68.3 ± 5.3 | 67.6 ± 5.2 |
| Sex: Female, Male(Participants) | Testosterone | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 155 | 151 | 306 |
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brigham and Women's Hospital